NCT00430300 - Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

UK-432,097

Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.

DRUG

Placebo

Capsules containing 100% lactose administered BID using an atomizer device

Trial Locations (22)

2037

Pfizer Investigational Site, Glebe

2050

Pfizer Investigational Site, Camperdown

5041

Pfizer Investigational Site, Daw Park

6009

Pfizer Investigational Site, Nedlands

T1Y 6J4

Pfizer Investigational Site, Calgary

T4N 6V7

Pfizer Investigational Site, Red Deer

L8N 3Z5

Pfizer Investigational Site, Hamilton

G1V 4G5

Pfizer Investigational Site, Québec

G8T 7A1

Pfizer Investigational Site, Trois-Rivières

7609 PP

Pfizer Investigational Site, Almelo

5623 EJ

Pfizer Investigational Site, Eindhoven

7207 BA

Pfizer Investigational Site, Zuthpen

85-326

Pfizer Investigational Site, Bydgoszcz

80-952

Pfizer Investigational Site, Gdansk

01-138

Pfizer Investigational Site, Warsaw

90-153

Pfizer Investigational Site, Lodz

KT16 0PZ

Pfizer Investigational Site, Chertsey

LE3 9QP

Pfizer Investigational Site, Leicester

E2 9ZY

Pfizer Investigational Site, London

M23 QZ

Pfizer Investigational Site, Manchester

NE7 7DN

Pfizer Investigational Site, Newcastle upon Tyne

SO16 6YD

Pfizer Investigational Site, Southampton